Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Bi-specific T-cell engagers as a bridge to ciltacabtagene autoleucel in Relapsed/Refractory multiple myeloma: Real-world outcomes in an underserved urban population

View Full Paper
Ask AI
Bookmark
Share

Authors

ECEmma CordoverBPBurak PolatEWElla Wesson

Discussion

Loading...

Member takes

Overview

Real-world outcomes show comparable efficacy and safety of bridge therapies in diverse RRMM patients, indicating improved access is essential.

Key Points

  • This research aimed to analyze the effectiveness and safety of BiTEs as a bridge to cilta-cel in underserved RRMM patients.
  • Single-center, retrospective chart review of RRMM patients treated with cilta-cel.
  • Subgroup analysis of patients who received BiTEs before cilta-cel infusion.
  • Safety and efficacy data were manually collected from electronic health records.
  • 49 RRMM patients received cilta-cel, with an overall response rate (ORR) of 91.9%.
  • CNS involvement was noted in 4.1% of patients, with 20% showing high-risk features as per IMWG.
  • 59% of BiTE-bridged patients experienced CRS compared to 81% of non-bridged patients.

Cite This Study

Cordover et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9d7https://doi.org/10.1182/blood-2025-4577
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma2025 · 5 citations
  2. 2Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma2025 · 3 citations
  3. 3Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma2025 · 10 citations
  4. 4P36 | EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER CILTACABTAGENE AUTOLEUCEL: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA2026
  5. 5The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma2025 · 2 citations